title: SAMe-TT2R2predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2experience.
abstract: A high SAMe-TT2R2score predicted poor warfarin control and adverse events among atrial fibrillation patients. However, the SAMe-TT2R2score has not been well validated in venous thromboembolism (VTE) patients. A cohort of 1943 warfarin-treated patients with acute VTE was analyzed to correlate the SAMe-TT2R2score with time in therapeutic range (TTR) and clinical adverse events. A TTR <60% was more frequent among patients with a high (>2) versus low (0-1) SAMe-TT2R2score (63.4% vs 52.3%, p<0.0001). A high SAMe-TT2R2score (>2) correlated with increased overall adverse events (7.9 vs 4.5 overall adverse events/100 patient years, p=0.002), driven primarily by increased recurrent VTE rates (4.2 vs 1.5 recurrent VTE/100 patient years, p=0.0003). The SAMe-TT2R2score had a modest predictive ability for international normalized ratio (INR) quality and adverse clinical events among warfarin-treated VTE patients. The utility of the SAMe-TT2R2score to guide clinical decision-making remains to be investigated.
authors.affiliation: 1 Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
authors.forename: Akash
authors.initials: A
authors.lastname: Kataruka
authors.affiliation: 2 Department of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Kong
authors.affiliation: 2 Department of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Haymart
authors.affiliation: 2 Department of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
authors.forename: Eva
authors.initials: E
authors.lastname: Kline-Rogers
authors.affiliation: 3 Department of Cardiology, William Beaumont Hospital, Royal Oak, MI, USA.
authors.forename: Steve
authors.initials: S
authors.lastname: Almany
authors.affiliation: 4 Huron Valley-Sinai Hospital, Commerce, MI, USA.
authors.forename: Jay
authors.initials: J
authors.lastname: Kozlowski
authors.affiliation: 5 Henry Ford Health System, Detroit, MI, USA.
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Krol
authors.affiliation: 5 Henry Ford Health System, Detroit, MI, USA.
authors.forename: Scott
authors.initials: S
authors.lastname: Kaatz
authors.affiliation: 6 The Spectrum Health Medical Group, Grand Rapids, MI, USA.
authors.forename: Michael W
authors.initials: MW
authors.lastname: McNamara
authors.affiliation: 2 Department of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
authors.forename: James B
authors.initials: JB
authors.lastname: Froehlich
authors.affiliation: 2 Department of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
authors.forename: Geoffrey D
authors.initials: GD
authors.lastname: Barnes
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D003661:Decision Support Techniques; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D044469:Racial Groups; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin
keywords: anticoagulants; pulmonary embolism; venous thromboembolism (VTE)